近期论文

查看导师新发文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1. Yi Li, Rui Cui, Tiejun Qin, Zefeng Xu, Yue Zhang, Wenyu Cai, Wen Cui, Jinqin Liu, Bing Li, Zhijian Xiao(corresponding author). Validation of the WHO 2016 proposals for Myelodysplastic syndromes patients with the presence of ring sideroblasts but without excess blasts. Br J Haematol,2016 2. Shi-Qiang Qu, Tie-Jun Qin, Ze-Feng Xu, Yue Zhang, Xiao-fei Ai, Bing Li, Hong-Li Zhang, Li-Wei Fang, Li-Juan Pan, Nai-Bo Hu, Zhi-Jian Xiao(corresponding author). Long-term outcomes of Imatinib in patients with FIP1L1/PDGFRA associated chronic eosinophilic leukemia：experience of a single center in China. Oncotarget, 2016，7(22):33229-33236 3. Feng G, Gale RP, Cui W, Cai W, Huang G, Xu Z, Qin T, Zhang Y, Li B, Fang L, Zhang H, Pan L, Hu N, Qu S, Wang J, Cui Y, Xiao Z(corresponding author). A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes. Exp Hematol Oncol. 2016 Apr 27;5:12. doi: 10.1186/ s40164-016-0041-6. eCollection 2015. 4. Li B, Xu Z, Li Y, Peter Gale R, Song Z, Ai X, Qin T, Zhang Y, Zhang P, Huang G, Xiao Z(corresponding author). The different prognostic impact of type-1 or type-1 like and type-2 or type-2 like CALR mutations in patients with primary myelofibrosis. Am J Hematol. 2016, 91(7):E320-321 5. Geyer HL, Andreasson B, Kosiorek HE, Dueck AC, Scherber RM, Martin KA, Butler KA, Harrison CN, Radia DH, Cervantes F, Kiladjian JJ, Reiter A, Birgegard G, Passamonti F, Senyak Z, Vannucchi AM, Paoli C, Xiao Z, Samuelsson J, Mesa RA. The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group. Cancer，2016，122(12):1888-1896 6. Holly Geyer, Robyn Scherber, Heidi Kosiorek, Amylou C. Dueck, Jean-Jacques Kiladjian, Zhijian Xiao, Stefanie Slot, Sonja Zweegman, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hern´andez-Maraver,Konstanze D¨ohner, Claire N. Harrison, Deepti Radia, Pablo Muxi, Carlos Besses, Francisco Cervantes,Peter L. Johansson, Bjorn Andreasson, Alessandro Rambaldi, Tiziano Barbui, Karin Bonatz, Andreas Reiter,Francoise Boyer, Gabriel Etienne, Jean-Christophe Ianotto, Dana Ranta, Lydia Roy, Jean-Yves Cahn,Norman Maldonado, Giovanni Barosi, Maria L. Ferrari, Robert Peter Gale, Gunnar Birgegard, Zefeng Xu,Yue Zhang, Xiujuan Sun, Junqing Xu, Peihong Zhang, Peter A.W. te Boekhorst, Suzan Commandeur, Harry Schouten, Heike L. Pahl, Martin Griesshammer, Frank Stegelmann, Thomas Lehmann, Zhenya Senyak,Alessandro M. Vannucchi, Francesco Passamonti, Jan Samuelsson, and Ruben A. Mesa. Symptomatic Profiles of Patients With Polycythemia Vera:Implications of Inadequately Controlled Disease. J Clin Oncol，2016，34(2):151-159 7. Wu X, Bekker-Jensen IH, Christensen J, Rasmussen KD, Sidoli S, Qi Y, Kong Y, Wang X, Cui Y, Xiao Z, Xu G, Williams K, Rappsilber J, Sønderby CK, Winther O, Jensen ON, Helin K. Tumor suppressor ASXL1 is essential for the activation of INK4B expression in response to oncogene activity and anti-proliferative signals. Cell Res, 2015 25(11):1205-18 8. Wu D, Du X, Jin J, Xiao Z, Shen Z, Shao Z, Li X, Huang X, Liu T, Yu L, Li J, Chen B, He G, Cai Z, Liang H, Li J, Ruan C. Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study. Adv Ther. 2015, 32(11):1140-59 9. Cui Y, Tong H, Du X, Li B, Gale RP, Qin T, Liu J, Xu Z, Zhang Y, Huang G, Jin J, Fang L, Zhang H, Pan L, Hu N, Qu S, Xiao Z(corresponding author). Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia. Exp Hematol Oncol, 2015,4:14. 10. Jung CW, Shih LY, Xiao Z, Jie J, Hou HA, Du X, Wang MC, Park S, Eom KS, Oritani K, Okamoto S, Tauchi T, Kim JS, Zhou D, Saito S, Li J, Handa H, Jianyong L, Ohishi K, Hou M, Depei W, Takenaka K, Liu T, Hu Y, Amagasaki T, Ito K, Gopalakrishna P, Akashi K. Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis. Leuk Lymphoma, 2015 ,56(7):2067-74 11. Li B, Gale R, Xiao Z(corresponding author). Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia. J Hematol Oncol, 2014, 7:93. 12. Cui Y, Li B, Gale R, Jiang Q, Xu Z, Qin T, Zhang P, Zhang Y, Xiao Z(corresponding author). CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia. J Hematol Oncol, 2014, 7:77. 13. Wang J, Xu J, Gale RP, Xu Z, Li B, Qin T, Zhang Y, Fang L, Zhang H, Pan L, Qu S, Zhang P, Xiao Z(corresponding author). Prognostic impact of splenomegaly on survival of Chinese with primary myelofibrosis. Leuk Res, 2014 , 38(10):1207-11 14. Li B, Xu J, Li C, Gale RP, Xu Z, Qin T, Zhang Y, Huang G, Fang L, Zhang H, Pan L, Hu N, Qu S, Xiao Z(corresponding author). Cytogenetic studies and their prognostic contribution in 565 Chinese patients with primary myelofibrosis. Am J Hematol, 2014, 89(11):1043-6 15. Wang J, Xiao Z(corresponding author). Mesenchymal stem cells in pathogenesis of myelodysplastic syndromes. Stem Cell Investigation 2014;1:16 16. Xing R, Li C, Gale RP, Zhang Y, Xu Z, Qin T, Li B, Fang L, Zhang H, Pan L, Hu N, Qu S, Xiao Z(corresponding author). Monosomal karyotype is an independent predictor of survival in patients with higher-risk myelodysplastic syndrome. Am J Hematol, 2014,;89(10):E163-168 17. Li B, Xu J, Wang J, Gale RP, Xu Z, Cui Y, Yang L, Xing R, Ai X, Qin T, Zhang Y, Zhang P, Xiao Z(corresponding author). Calreticulin mutations in Chinese with primary myelofibrosis. Haematologica, 2014，99: 1697-1700 18. Cui R, Gale RP, Zhu G, Xu Z, Qin T, Zhang Y, Huang G, Li B, Fang L, Zhang H, Pan L, Hu N, Qu S, Xiao Z(corresponding author). Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions. Leuk Res, 2014, 38(5):545-50. 19. Geyer HL, Scherber RM, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernández-Maraver D, Döhner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Vannucchi AM, Passamonti F, Samuelsson J, Birgegard G, Mesa RA. Distinct clustering of symptomatic burden amongst myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood, 2014, 123(24):3803-3810 20. Zhao X, Chen A, Yan X, Zhang Y, He F, Hayashi Y, Dong Y, Rao Y, Li B, Conway RM, Maiques-Diaz A, Elf SE, Huang N, Zuber J, Xiao Z, Tse W, Tenen DG, Wang Q, Chen W, Mulloy JC, Nimer SD, Huang G. Down-regulation of RUNX1/CBFβ by MLL fusion proteins enhances HSC self-renewal. Blood, 2014, 123(11):1729-38.